Core Viewpoint - The company is currently not involved in the brain-computer interface sector but will closely monitor developments in this industry [1] Group 1: AI Technology in Drug Development - The company utilizes AI technology in its innovative drug research, specifically in AIDD (Artificial Intelligence Drug Discovery) and CADD (Computer-Aided Drug Design) [1] - The company has developed its own AI platform, known as the Smart Drug AI platform, which can be applied to toxicity prediction as well as activity and drug-likeness prediction [1] Group 2: Organoid Platform and Drug Development Services - The company's organoid platform provides drug development technical services, including drug screening, efficacy evaluation, and safety assessment [1] - This platform aims to enhance the precision and efficiency of drug development processes [1]
百诚医药：目前公司尚未涉足脑机接口领域